VAXCELL-BIO THERAPEUTICS CO., LTD. Vaxcell-Bio Therapeutics Co., Ltd. Stock
Equities
A323990
KR7323990002
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16,390 KRW | +0.37% |
|
-3.98% | -26.99% |
| 2023 | Vaxcell-Bio Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2021 | Vaxcell-Bio Therapeutics Co., Ltd.(KOSDAQ:A323990) added to S&P Global BMI Index | CI |
| Sales 2022 | - | Sales 2023 | 13.72 18.87K 18.83 | Capitalization | 516B 709,725B 708B |
|---|---|---|---|---|---|
| Net income 2022 | -6.82B -9,384B -9.37B | Net income 2023 | -10.27B -14,126B -14.1B | EV / Sales 2022 | - |
| Net cash position 2022 | 20.29B 27,893B 27.84B | Net cash position 2023 | 49.69B 68,312B 68.19B | EV / Sales 2023 | 33,994,130,725 x |
| P/E ratio 2022 |
-63.5
x | P/E ratio 2023 |
-42.8
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 76.05% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.37% | ||
| 1 week | -3.98% | ||
| Current month | -20.82% | ||
| 1 month | -20.82% | ||
| 3 months | -17.60% | ||
| 6 months | -19.06% | ||
| Current year | -26.99% |
1 week
14 350.00
17 200.00
1 month
14 350.0021 200.00
Current year
14 350.0024 950.00
1 year
14 350.0047 416.67
3 years
14 350.0087 333.33
5 years
8 520.83249 750.00
10 years
8 520.83249 750.00
| Managers | Title | Age | Since |
|---|---|---|---|
Joon-Haeng Lee
CEO | Chief Executive Officer | 64 | - |
Jae-Jung Lee
CEO | Chief Executive Officer | 60 | 10-02-17 |
Taek-Gun Oh
AUD | Comptroller/Controller/Auditor | 48 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sung-Chang Jung
BRD | Director/Board Member | 67 | - |
Jae-Jung Lee
CEO | Chief Executive Officer | 60 | 10-02-17 |
Joon-Haeng Lee
CEO | Chief Executive Officer | 64 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 16,390 | +0.37% | 87,738 |
| 24-04-29 | 16,330 | +3.68% | 132,104 |
| 24-04-26 | 15,750 | -1.87% | 151,997 |
| 24-04-25 | 16,050 | -1.53% | 131,019 |
| 24-04-24 | 16,300 | -5.23% | 1,142,262 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
Vaxcell-Bio Therapeutics is a Korea-based company mainly engaged in the research and development of anti-angiogenic immunotherapy drugs. The Company's pipeline consists of the Vax-NK natural killer cell anti-cancer immunotherapy platforms, the Vax-DC dendritic cell anti-cancer immunotherapy platforms, and the Vax-CAR series next-generation advanced anti-cancer immunotherapy platforms. In addition, the Company manufactures and sells cytokine-based boxleukin-15, an anticancer immunotherapy exclusively for dogs. The Company sells its products in domestic and overseas markets.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -26.99% | 272M | |
| -1.17% | 104B | |
| +2.87% | 97.47B | |
| +4.37% | 22.25B | |
| -14.77% | 21.68B | |
| -9.00% | 18.2B | |
| -39.98% | 17.02B | |
| -13.21% | 16.36B | |
| +8.55% | 14.39B | |
| +35.75% | 12.37B |
- Stock Market
- Equities
- A323990 Stock
